Exclusive Summary

• UB032 is a bispecific antibody-drug conjugate (BsAb-ADC) targeting both Nectin-4 and Trop2, demonstrating superior efficacy and potentially lower toxicity compared to single-target ADCs or combination therapies.
• The product shows significant in vitro and in vivo anti-tumor activity in various solid tumors that highly express Nectin-4 and Trop2, such as bladder cancer, cervical cancer, lung cancer, and pancreatic cancer, addressing limitations of existing treatments.
• UB032 exhibits excellent CMC developability (monomer purity >99%, Tm 64.5°C) and accelerated stability, reducing late-stage development and commercialization risks.
• Compared to Nectin-4 or Trop2 single-target ADCs, UB032 demonstrates stronger killing effects in dual-positive tumor models, possessing First-in-Class or Best-in-Class potential, particularly in bladder and cervical cancers.
• The Chinese supplier background and potential license-out cooperation model offer overseas pharmaceutical companies a fast-track opportunity to enter the innovative ADC market and expand their global oncology pipeline.

Asset Materials

Contact Us for Full Materials